Shanghai Historical Income Statement

601607 Stock

19.36 0.22 1.12%

Historical analysis of Shanghai Pharmaceuticals income statement accounts such as Selling General Administrative of 18.9 B, Total Revenue of 314.3 B or Operating Income of 11.5 B can show how well Shanghai Pharmaceuticals Holding performed in making a profits. Evaluating Shanghai Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Shanghai Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Shanghai Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Shanghai Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Shanghai Income Statement Analysis

Shanghai Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Shanghai Pharmaceuticals shareholders. The income statement also shows Shanghai investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Shanghai Pharmaceuticals Income Statement Chart

At present, Shanghai Pharmaceuticals' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 18.9 B, whereas Net Income is forecasted to decline to about 2.2 B.

Selling General Administrative Total Revenue Operating Income Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Shanghai Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Shanghai Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Shanghai Pharmaceuticals Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Shanghai Pharmaceuticals income statement and represents the costs associated with goods and services Shanghai Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Shanghai Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Shanghai Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Operating Income	8.8B	9.6B	11.0B	11.5B
Total Revenue	232.0B	260.3B	299.3B	314.3B

Operating Income Total Revenue

Shanghai Pharmaceuticals income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		0.98	0.98	0.98	0.97	0.73	0.97	-0.07	0.93	0.9	0.82	0.85	0.87	0.87	-0.88	0.86	-0.9	0.79	0.85	0.82
Total Revenue	0.98		0.99	1.0	0.95	0.66	0.98	-0.17	0.97	0.91	0.84	0.85	0.89	0.9	-0.85	0.88	-0.87	0.84	0.88	0.83
Operating Income	0.98	0.99		0.99	0.95	0.66	0.98	-0.18	0.98	0.92	0.86	0.87	0.89	0.91	-0.89	0.91	-0.88	0.85	0.9	0.87
Cost Of Revenue	0.98	1.0	0.99		0.94	0.65	0.97	-0.18	0.97	0.9	0.84	0.84	0.88	0.9	-0.85	0.88	-0.86	0.84	0.88	0.83
Income Before Tax	0.97	0.95	0.95	0.94		0.83	0.97	-0.08	0.92	0.88	0.83	0.91	0.88	0.84	-0.86	0.87	-0.88	0.78	0.83	0.77
Net Income	0.73	0.66	0.66	0.65	0.83		0.72	0.18	0.63	0.75	0.73	0.8	0.77	0.69	-0.69	0.7	-0.74	0.6	0.65	0.59
Income Tax Expense	0.97	0.98	0.98	0.97	0.97	0.72		-0.19	0.96	0.9	0.84	0.88	0.88	0.88	-0.88	0.92	-0.86	0.83	0.88	0.81
Minority Interest	-0.07	-0.17	-0.18	-0.18	-0.08	0.18	-0.19		-0.24	-0.11	-0.23	-0.17	-0.01	-0.25	0.1	-0.28	0.01	-0.44	-0.33	-0.09
Research Development	0.93	0.97	0.98	0.97	0.92	0.63	0.96	-0.24		0.92	0.88	0.89	0.9	0.92	-0.89	0.92	-0.88	0.88	0.91	0.84
Gross Profit	0.9	0.91	0.92	0.9	0.88	0.75	0.9	-0.11	0.92		0.94	0.92	0.96	0.98	-0.94	0.96	-0.95	0.91	0.96	0.91
Other Operating Expenses	0.82	0.84	0.86	0.84	0.83	0.73	0.84	-0.23	0.88	0.94		0.91	0.88	0.95	-0.83	0.92	-0.85	0.92	0.93	0.81
Net Income From Continuing Ops	0.85	0.85	0.87	0.84	0.91	0.8	0.88	-0.17	0.89	0.92	0.91		0.91	0.88	-0.91	0.91	-0.92	0.84	0.89	0.81
Ebit	0.87	0.89	0.89	0.88	0.88	0.77	0.88	-0.01	0.9	0.96	0.88	0.91		0.93	-0.9	0.92	-0.89	0.85	0.9	0.86
Total Operating Expenses	0.87	0.9	0.91	0.9	0.84	0.69	0.88	-0.25	0.92	0.98	0.95	0.88	0.93		-0.89	0.97	-0.88	0.96	0.98	0.9
Total Other Income Expense Net	-0.88	-0.85	-0.89	-0.85	-0.86	-0.69	-0.88	0.1	-0.89	-0.94	-0.83	-0.91	-0.9	-0.89		-0.92	0.96	-0.82	-0.9	-0.88
Tax Provision	0.86	0.88	0.91	0.88	0.87	0.7	0.92	-0.28	0.92	0.96	0.92	0.91	0.92	0.97	-0.92		-0.87	0.94	0.97	0.87
Net Interest Income	-0.9	-0.87	-0.88	-0.86	-0.88	-0.74	-0.86	0.01	-0.88	-0.95	-0.85	-0.92	-0.89	-0.88	0.96	-0.87		-0.78	-0.85	-0.84
Interest Income	0.79	0.84	0.85	0.84	0.78	0.6	0.83	-0.44	0.88	0.91	0.92	0.84	0.85	0.96	-0.82	0.94	-0.78		0.98	0.88
Ebitda	0.85	0.88	0.9	0.88	0.83	0.65	0.88	-0.33	0.91	0.96	0.93	0.89	0.9	0.98	-0.9	0.97	-0.85	0.98		0.93
Reconciled Depreciation	0.82	0.83	0.87	0.83	0.77	0.59	0.81	-0.09	0.84	0.91	0.81	0.81	0.86	0.9	-0.88	0.87	-0.84	0.88	0.93

Click cells to compare fundamentals

Shanghai Pharmaceuticals Account Relationship Matchups

Shanghai Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Interest Expense	1.4B	1.5B	1.7B	1.7B	1.9B	2.0B
Selling General Administrative	14.2B	14.7B	15.5B	15.6B	18.0B	18.9B
Total Revenue	191.9B	215.8B	232.0B	260.3B	299.3B	314.3B
Operating Income	8.1B	7.9B	8.8B	9.6B	11.0B	11.5B
Cost Of Revenue	164.5B	187.3B	201.5B	229.0B	263.3B	276.5B
Income Before Tax	7.2B	8.1B	8.8B	7.1B	8.1B	8.5B
Net Income Applicable To Common Shares	3.9B	4.1B	4.5B	5.1B	5.9B	6.2B
Net Income	4.5B	5.1B	5.6B	3.8B	4.3B	2.2B
Income Tax Expense	1.4B	1.6B	1.9B	1.8B	2.1B	2.2B
Minority Interest	9.4B	(1.2B)	(1.4B)	(1.4B)	(1.6B)	(1.5B)
Research Development	1.7B	2.0B	2.1B	2.2B	2.5B	2.7B
Gross Profit	27.4B	28.5B	30.5B	31.3B	36.0B	25.7B
Other Operating Expenses	509.0M	380.4M	587.3M	633.2M	728.2M	503.2M
Net Income From Continuing Ops	5.6B	6.3B	7.0B	5.2B	5.9B	5.4B
Ebit	5.4B	7.1B	7.3B	7.5B	8.6B	6.6B
Total Operating Expenses	183.8B	207.9B	223.2B	250.7B	288.3B	188.4B
Tax Provision	1.6B	1.9B	1.8B	1.9B	2.2B	1.6B
Net Interest Income	(1.2B)	(1.3B)	(1.3B)	(1.3B)	(1.1B)	(1.2B)
Interest Income	288.3M	338.2M	438.3M	461.8M	531.1M	315.1M
Ebitda	9.5B	10.7B	10.7B	12.7B	14.6B	10.7B
Reconciled Depreciation	2.1B	1.1B	2.2B	2.2B	2.5B	1.8B

Currently Active Assets on Macroaxis

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin
ADA	Cardano
XRP	XRP

Other Information on Investing in Shanghai Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Shanghai Historical Income Statement

About Shanghai Income Statement Analysis

Shanghai Pharmaceuticals Income Statement Chart

Total Revenue

Operating Income

Cost Of Revenue

Shanghai Pharmaceuticals income statement Correlations

Shanghai Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Shanghai Pharmaceuticals income statement Accounts

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Total Revenue
Operating Income	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Operating Income
Total Revenue	+ 0.98	Selling General Administrative
Operating Income	+ 0.98	Selling General Administrative
Cost Of Revenue	+ 0.98	Selling General Administrative

Net Interest Income	- 0.95	Gross Profit
Total Other Income Expense Net	- 0.94	Gross Profit
Tax Provision	- 0.92	Total Other Income Expense Net
Net Interest Income	- 0.92	Net Income From Continuing Ops
Total Other Income Expense Net	- 0.91	Net Income From Continuing Ops
Ebitda	- 0.9	Total Other Income Expense Net